279 related articles for article (PubMed ID: 21740480)
1. Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily.
Amodio E; Goedert JJ; Barozzi P; Riva G; Firenze A; Bonura F; Viviano E; Romano N; Luppi M
Cancer Sci; 2011 Oct; 102(10):1769-73. PubMed ID: 21740480
[TBL] [Abstract][Full Text] [Related]
2. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS
J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173
[TBL] [Abstract][Full Text] [Related]
3. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study.
Wakeham K; Johnston WT; Nalwoga A; Webb EL; Mayanja BN; Miley W; Elliott AM; Whitby D; Newton R
Int J Cancer; 2015 Jun; 136(12):2822-30. PubMed ID: 25395177
[TBL] [Abstract][Full Text] [Related]
4. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells.
Zhu L; Wang R; Sweat A; Goldstein E; Horvat R; Chandran B
Virology; 1999 Apr; 256(2):381-92. PubMed ID: 10191203
[TBL] [Abstract][Full Text] [Related]
5. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma.
Guihot A; Dupin N; Marcelin AG; Gorin I; Bedin AS; Bossi P; Galicier L; Oksenhendler E; Autran B; Carcelain G
J Infect Dis; 2006 Oct; 194(8):1078-88. PubMed ID: 16991082
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.
Newton R; Carpenter L; Casabonne D; Beral V; Babiker A; Darbyshire J; Weller I; Weiss R; Kwan A; Bourboulia D; Munoz F; Lagos D; Boshoff C
Br J Cancer; 2006 May; 94(10):1504-9. PubMed ID: 16705315
[TBL] [Abstract][Full Text] [Related]
7. Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency.
Mariggiò G; Koch S; Zhang G; Weidner-Glunde M; Rückert J; Kati S; Santag S; Schulz TF
PLoS Pathog; 2017 Apr; 13(4):e1006335. PubMed ID: 28430817
[TBL] [Abstract][Full Text] [Related]
8. Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins.
Woodberry T; Suscovich TJ; Henry LM; Martin JN; Dollard S; O'Connor PG; Davis JK; Osmond D; Lee TH; Kedes DH; Khatri A; Lee J; Walker BD; Scadden DT; Brander C
J Infect Dis; 2005 Aug; 192(4):622-9. PubMed ID: 16028131
[TBL] [Abstract][Full Text] [Related]
9. Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls.
Valenti RM; Amodio E; Nam JM; Preiss L; Graubard BI; Romano N; Goedert JJ
Br J Cancer; 2011 Feb; 104(3):433-6. PubMed ID: 21245864
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen.
Simpson GR; Schulz TF; Whitby D; Cook PM; Boshoff C; Rainbow L; Howard MR; Gao SJ; Bohenzky RA; Simmonds P; Lee C; de Ruiter A; Hatzakis A; Tedder RS; Weller IV; Weiss RA; Moore PS
Lancet; 1996 Oct; 348(9035):1133-8. PubMed ID: 8888167
[TBL] [Abstract][Full Text] [Related]
11. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma.
Engels EA; Biggar RJ; Marshall VA; Walters MA; Gamache CJ; Whitby D; Goedert JJ
AIDS; 2003 Aug; 17(12):1847-51. PubMed ID: 12891072
[TBL] [Abstract][Full Text] [Related]
12. Kaposi sarcoma-associated herpesvirus, HIV-1 and Kaposi sarcoma risk in black South Africans diagnosed with cancer during antiretroviral treatment rollout.
Motlhale M; Muchengeti M; Bradshaw D; Chen WC; Singini MG; de Villiers CB; Lewis CM; Bender N; Mathew CG; Newton R; Waterboer T; Singh E; Sitas F
Int J Cancer; 2023 May; 152(10):2081-2089. PubMed ID: 36727526
[TBL] [Abstract][Full Text] [Related]
13. Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA.
Mbisa GL; Miley W; Gamache CJ; Gillette WK; Esposito D; Hopkins R; Busch MP; Schreiber GB; Little RF; Yarchoan R; Ortiz-Conde BA; Labò N; Whitby D
J Immunol Methods; 2010 Apr; 356(1-2):39-46. PubMed ID: 20211626
[TBL] [Abstract][Full Text] [Related]
14. Human herpesvirus 8/Kaposi sarcoma herpesvirus cell association during evolution of Kaposi sarcoma.
Pyakurel P; Massambu C; Castaños-Vélez E; Ericsson S; Kaaya E; Biberfeld P; Heiden T
J Acquir Immune Defic Syndr; 2004 Jun; 36(2):678-83. PubMed ID: 15167286
[TBL] [Abstract][Full Text] [Related]
15. The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals.
Guedes F; de Andrade HF; Fernandes ER; Tuon FF; Brasil RA; Pagliari C; Duarte MI
Br J Dermatol; 2008 Sep; 159(4):839-46. PubMed ID: 18644020
[TBL] [Abstract][Full Text] [Related]
16. Kaposi's sarcoma-associated herpesvirus seroprevalence in selected german patients: evaluation by different test systems.
Preiser W; Szép NI; Lang D; Doerr HW; Rabenau HF
Med Microbiol Immunol; 2001 Dec; 190(3):121-7. PubMed ID: 11827200
[TBL] [Abstract][Full Text] [Related]
17. A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma.
Brown EE; Fallin MD; Goedert JJ; Chen R; Whitby D; Foster CB; Lauria C; Alberg AJ; Messina A; Montella M; Rezza G; Vitale F; Chanock SJ;
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):633-7. PubMed ID: 15767342
[TBL] [Abstract][Full Text] [Related]
18. Identification, expression, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen.
Lin SF; Sun R; Heston L; Gradoville L; Shedd D; Haglund K; Rigsby M; Miller G
J Virol; 1997 Apr; 71(4):3069-76. PubMed ID: 9060668
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
20. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma.
Kimball LE; Casper C; Koelle DM; Morrow R; Corey L; Vieira J
J Infect Dis; 2004 Jun; 189(11):2016-22. PubMed ID: 15143468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
